Dr. Schrappe discusses results of the AIEOP-BFM ALL 2000 trial, presented as a plenary abstract at the 2016 ASH Annual Meeting.
Martin Schrappe, MD: Attempting to Reduce Chemotherapy Burden in Children With ALL
Recent Articles
New Rules of the Road in TTP Management
In July 2020, the International Society on Thrombosis and Haemostasis (ISTH) issued its first-ever guidelines for the treatment of thrombotic thrombocytopenic purpura (TTP), helping...
The Year in FDA Approvals
Here, we review recent therapies approved by the U.S. Food and Drug Administration for the treatment of red blood cell and iron disorders, including...
Hydroxyurea Treatment Before Puberty Does Not Impair Future Sperm Quality in Boys With SCD
Childhood hydroxyurea (hydroxycarbamide) treatment does not impair future sperm parameters in boys with severe sickle cell disease (SCD), according research published in Blood. These...
Investigating Tyrosine Kinase Inhibitors for ITP
In two presentations presented at EHA25 Virtual, the 25th European Hematology Association Annual Congress, investigators shared updates on two kinase inhibitors for the treatment...
Tranexamic Acid for Gastrointestinal Bleeding: Time to HALT-IT?
Although tranexamic acid reduces the risks of surgical bleeding and bleeding-related death in patients with trauma, it does not reduce risk of death from...
Current Issue
September 2020 Volume 6, Issue 11
This issue features a look at the evolution of preprint platforms, an analysis of the economic and health consequences of the COVID-19 pandemic, and more.